Davita Inc (NYSE:DVA) – Research analysts at SunTrust Banks issued their Q1 2018 EPS estimates for Davita in a note issued to investors on Tuesday, Zacks Investment Research reports. SunTrust Banks analyst D. Macdonald forecasts that the company will post earnings per share of $0.89 for the quarter. SunTrust Banks also issued estimates for Davita’s Q2 2018 earnings at $0.97 EPS, Q3 2018 earnings at $1.01 EPS, Q4 2018 earnings at $0.95 EPS and FY2019 earnings at $4.17 EPS.
Other analysts have also issued research reports about the stock. TheStreet upgraded shares of Davita from a “c+” rating to a “b-” rating in a research note on Monday, April 3rd. Zacks Investment Research upgraded shares of Davita from a “hold” rating to a “buy” rating and set a $77.00 price objective on the stock in a research note on Tuesday. Finally, Royal Bank of Canada reissued a “hold” rating and set a $62.00 price target on shares of Davita in a research report on Friday, February 17th. Seven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Davita has a consensus rating of “Hold” and a consensus price target of $70.33.
COPYRIGHT VIOLATION NOTICE: “Q1 2018 Earnings Forecast for Davita Inc (DVA) Issued By SunTrust Banks” was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.chaffeybreeze.com/2017/04/21/suntrust-banks-weighs-in-on-davita-incs-q1-2018-earnings-dva-updated.html.
Shares of Davita (NYSE:DVA) traded down 0.92% during trading on Thursday, reaching $67.80. 275,130 shares of the company’s stock were exchanged. The stock has a 50 day moving average price of $67.93 and a 200-day moving average price of $64.57. Davita has a 52 week low of $54.50 and a 52 week high of $78.77. The stock has a market capitalization of $13.19 billion, a price-to-earnings ratio of 15.80 and a beta of 1.02.
Davita (NYSE:DVA) last issued its earnings results on Thursday, February 16th. The company reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.91 by $0.07. Davita had a net margin of 4.92% and a return on equity of 16.16%. The company had revenue of $3.72 billion for the quarter, compared to the consensus estimate of $3.74 billion. During the same period in the previous year, the firm earned $1.12 earnings per share. Davita’s quarterly revenue was up 5.2% compared to the same quarter last year.
Several institutional investors have recently made changes to their positions in DVA. SRS Capital Advisors Inc. purchased a new position in shares of Davita during the fourth quarter valued at about $118,000. Raymond James Trust N.A. purchased a new position in shares of Davita during the first quarter valued at about $202,000. Seven Bridges Advisors LLC increased its position in shares of Davita by 187.1% in the third quarter. Seven Bridges Advisors LLC now owns 3,066 shares of the company’s stock valued at $203,000 after buying an additional 1,998 shares during the period. Acrospire Investment Management LLC increased its position in shares of Davita by 166.7% in the third quarter. Acrospire Investment Management LLC now owns 3,200 shares of the company’s stock valued at $211,000 after buying an additional 2,000 shares during the period. Finally, Parametrica Management Ltd purchased a new position in shares of Davita during the first quarter valued at about $237,000. 85.31% of the stock is owned by institutional investors.
Davita Company Profile
DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Davita Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita Inc and related companies with MarketBeat.com's FREE daily email newsletter.